Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

93.91 -0.90 (-0.95%)
Streaming Delayed Price Updated: 11:15 AM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
News headline image
Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box. ↗
RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines in favor of his nomination. 
Via Investor's Business Daily
News headline image
Pfizer Edges Higher As Covid Sales Decline, But Still Beat Expectations ↗
Pfizer stock rose moderately early Tuesday on the back of its quarterly beat. 
Via Investor's Business Daily
News headline image
BioNTech Completes Acquisition of Biotheus
From BioNTech SE
Via GlobeNewswire
News headline image
Peering Into BioNTech's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why BioNTech (BNTX) Shares Are Volatile Today ↗
Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which fell below analyst expectations. 
Via Benzinga
News headline image
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots ↗
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. 
Via Investor's Business Daily
News headline image
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection ↗
Via The Motley Fool
News headline image
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
News headline image
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell? ↗
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
News headline image
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
News headline image
Critical Insights From BioNTech Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst ↗
Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025. 
Via Benzinga
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
News headline image
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike ↗
Moderna, BioNTech and Novavax stocks popped after the CDC noted a recent increase in positive Covid tests. 
Via Investor's Business Daily
News headline image
The Analyst Landscape: 17 Takes On BioNTech ↗
 
Via Benzinga
News headline image
5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right ↗
Via The Motley Fool
News headline image
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy ↗
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS. 
Via Investor's Business Daily
News headline image
3 No-Brainer Biotech Stocks to Buy With $200 Right Now ↗
Via The Motley Fool
News headline image
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid ↗
Via The Motley Fool
News headline image
2 No-Brainer Stocks to Buy Before the End of 2024 ↗
Via The Motley Fool
News headline image
Why Is BioNTech Stock Trading Higher On Friday? ↗
BNT324/DB-1311 trial data show significant antitumor activity in various cancers, with high response rates in small cell lung and prostate cancer patients. 
Via Benzinga
News headline image
5 Top Stocks to Buy in December ↗
Take a closer look at these bargain-bin value stocks, quality dividend stocks, and one scorching-hot growth stock. 
Via The Motley Fool
News headline image
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth ↗
To gain an edge, this is what you need to know today. 
Via Benzinga
News headline image
European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
News headline image
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS ↗
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
News headline image
BioNTech Stock Got A IBD RS Rating Lift ↗
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
News headline image
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition ↗
BioNTech acquires Biotheus for $800 million plus milestone payments, securing global rights to BNT327/PM8002 and expanding its oncology and R&D presence in China. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.